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Background/aim: To explore the frequency and clinical associations of radiologic pleuroparenchymal fibroelastosis (PPFE) in patients
with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Materials and methods: In this single-center retrospective study, high resolution computed tomography (HRCT) images of 105 patients
with SSc-ILD were examined for the presence of PPFE. Demographic, clinical, laboratory, and pulmonary function test (PFT) data of
patients with and without PPFE were compared.
Results: PPFE was detected in 19 (18.1%) patients (‘definite PPFE’ in 13 and ‘consistent with PPFE’ in 6 patients). Patients with PPFE
had higher age and longer disease duration than PPFE (-) patients (p < 0.05 for both). Radiologic usual interstitial pneumoniae (UIP)
pattern was more frequent (26.3% vs. 4.7%, p = 0.01) and median force vital capacity (FVC) was lower in patients with PPFE (64% vs.
82%, p = 0.005). Spontaneous pneumothorax developed in one patient with PPFE. More deaths occured in PPFE (+) group during
follow-up (31% vs. 11%, p = 0.04).
Conclusion: PPFE on HRCT is not uncommon in SSc-ILD and is associated with radiologic UIP pattern and worse lung functions.
Further studies are needed to elucidate the prognostic value of PPFE in SSc-ILD.
Key words: Systemic sclerosis, interstitial lung disease, pleuroparenchymal fibroelastosis

1. Introduction
Interstitial lung disease (ILD) is a major complication of
systemic sclerosis (SSc) and one of the leading causes of
mortality and morbidity [1]. Up to 80% of SSc patients
had evidence of ILD on high resolution computed
tomography (HRCT) however, about %30 of them develop
progressive lung fibrosis [2]. Nonspecific interstitial
pneumoniae (NSIP) is the most frequent histopathologic
and radiologic pattern of SSc-ILD and predominantly
involves lower lobes of the lungs [3,4]. Other ILD
patterns including usual interstitial pneumoniae (UIP),
respiratory bronchiolitis associated ILD and organising
pneumoniae are less commonly observed in the course of
SSc [4]. Pleuroparenchymal fibroelastosis (PPFE) is a rare
disorder characterised by the fibrosis of visceral pleura
and the subpleural parenchymal areas of upper lobes
[5]. Idiopathic form of PPFE has been listed within the
classification of idiopathic interstitial pneumoniaes [6].
On the other hand, PPFE can also occur in association
with other conditions including infections, lung or bone
marrow transplantation, hypersensitivity pneumonitis,

and connective tissue diseases [7]. Little data exists on the
frequency and clinical significance of radiological PPFElike lesions in SSc-ILD [8,9]. This study aims to explore the
frequency of PPFE and its association with clinical features
in a single-center SSc-ILD cohort.
2. Materials and methods
We retrospectively reviewed the charts of patients with
SSc seen in outpatient rheumatology department between
April 2015 and July 2018. Patients with ILD and available
high-resolution computed tomography (HRCT) scan in
our institute were identified and included in the study. In
all included patients’ classification criteria for SSc proposed
by ACR/EULAR in 2013 were met and the diagnosis of
ILD had been made with HRCT [10]. Data for selected
demographic and clinical characteristics including age,
sex, disease duration (time from the onset of first nonRaynaud symptom attributable to SSc), survival status,
disease subtype (limited/diffuse), organ manifestations,
autoantibody specifity, and treatment details were collected.
Pulmonary arterial hypertension (PAH) was defined as
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resting mean pulmonary arterial pressure (mPAP) ≥ 25
mmHg and pulmonary capillary wedge pressure (PCWP)
< 15 mmHg by right heart catheterisation in the absence
of other causes of precapillary pulmonary hypertension
[11]. Data for forced vital capacity (FVC) was collected if
performed within 12 months of HRCT and expressed as a
percentage of predicted values.
The first available HRCT scan of each patient was
separately evaluated by two radiologists with 2-year and
over 30-year experience in thorax radiology, blinded to
clinical information. ‘Definite PPFE’ was defined as upperlobe predominant pleural thickening with associated
subpleural fibrosis with minimal or no involvement of
lower lobes (Figure a). Radiologic lesion ‘consistent with
PPFE’ was used for the cases where upper lobe pleural
thickening with associated subpleural fibrosis was
observed but 1) not mainly located in the upper lobes or
2) with features of coexistent disease elsewhere (Figure
b) [12]. Additionally, cases with extension to the apical
region with a pattern similar to the basal involvement
were also included in this group (consistent with PPFE).
Patients with ‘definite’ and ‘consistent with’ PPFE lesions
were both included in the PPFE (+) group. Patients with
apical lesions which are considered secondary to another
pathology such as pneumoconiosis and “patients with
apical cap” were not included in the PPFE (+) group.
‘Apical cap’ was defined as irregular subpleural opacities
smaller than 5 mm diameter and located in the apical
region (Figure c). The radiologic pattern of ILD was also
classified according to the American Thoracic Society/
European Respiratory Society Statement (2013) and
Fleischner society guidelines (2018) [6,13]. Patients with
NSIP pattern were further classified as having a cellular or
fibrotic pattern. Traction bronchiectasis, lung volume loss,
axial interstitial thickening and coarse reticular opacities
were considered as imaging features of fibrotic NSIP.
Cellular NSIP was defined as the presence of only fine
reticular opacities and/or ground glass opacities without
any of the fibrotic NSIP features [14]. The extent of ILD on
HRCT was classified as ‘limited’ or ‘extensive’ according to
the staging system described by Goh et al [15]. Emphysema
on HRCT was defined as subpleural well-defined cystic
areas (paraseptal) and/or low-attenuation areas smaller
than 1 cm located in the center of the secondary pulmonary
lobule (centrilobular) [16]. Two separate measurements
for the proximal 2/3 of the esophagus were made superior
and inferior to the aortic arch in axial plane of HRCT
scans, respectively. The largest distances between the
internal esophageal mucosal borders were measured in the
soft tissue window. A distance of >10 mm was considered
as esophageal dilatation [17]. Disagreements between
radiologists were resolved by consensus.
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2.1. Statistical analysis
Statistical analysis was performed using SPSS Statistics for
Windows version 21.0. Categorical variables were expressed
as a percentage. Continuous variables were expressed as
mean (standard deviation, SD) for normally distributed
data or median (interquartile range, IQR) for skewed
data. Normality of data was assessed using KolmogorovSmirnov test. Chi-square and Fisher’s exact tests were
used to compare categorical variables. Student’s-t test or
Mann Whitney-U test were used to compare continuous
variables between independent groups. A significance
level of 0.05 was used for all statistical tests.
3. Results
Among 284 patients with SSc, 152 (53.5 %) had ILD and
105 (93 females) had available HRCT scans. Mean age at
disease onset and first available HRCT were 40.8 (13.0)
and 49.5 (12.4) years, respectively. The median disease
duration was 6.8 (2.0-13.6) years. Thirty- three (32.3%)
patients had diffuse disease and 9 (8.8%) patients had
overlapping myositis. One (0.9%) patient had scleroderma
renal crisis. Most of the patients (67.6%) had positive
serology for antitopoisomerase antibodies.
The radiologic pattern of ILD on HRCT was consistent
with NSIP in 95 (90.4%), UIP in 9 (8.5%) and bronchiolitis
obliterans organizing pneumoniae (BOOP) in 1 patient.
Among patients with NSIP pattern, 81 (85.3%) had
fibrotic and 14 (14.7%) had cellular NSIP. Apical lesions
on HRCT were present in 38 (36.2%) patients. After
excluding 18 patients with apical cap and 1 patient with
pneumoconiosis (silicosis), PPFE-like lesions on HRCT
were present in 19 (18.1%) patients (‘definite PPFE’ in 13
and ‘consistent with PPFE’ in 6 patients). Demographic
and clinical characteristics of patients by PPFE-like lesion
status are summarized in Table. Compared to PPFE (-)
ones, patients with PPFE were older and had a longer
disease duration (p < 0.05 for both). Radiologic UIP
pattern was more frequent in patients with PPFE (26.3%
vs. 4.7%, p = 0.01). PPFE was present in 17.3% of patients
with fibrotic NSIP and none of the patients with cellular
NSIP (p = 0.12). The median time period between HRCT
and FVC measurement was 0.7 (0.06–3.16) months.
Patients with PPFE had lower median FVC than those
without (64% vs. 82%, p = 0.005). Although follow-up
duration after the first available HRCT was shorter, more
deaths occurred in the PPFE (+) patients during this
period (31% vs. 11%, p = 0.04). Causes of deaths were as
follows: in PPFE (+) group; PAH in 1, pneumoniae in 1,
gastrointestinal haemorrhage and sepsis in 1, lung cancer
in 1, unknown in 2 patients, in PPFE (-) group; PAH in
2, lung cancer in 1, acute leukemia in 1, sepsis due to
osteomyelitis in 1, pneumoniae in 1, heart failure in 1,
pneumoniae/exacerbation of ILD in 1, scleroderma renal
crisis in 1 and unknown in 1 patient. Myositis overlap was
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Figure a. Definite PPFE.

Figure b. Consistent with PPFE.

Figure c. ApicalCap.
Figure a,b,c. High resolution thorax tomography images of pleuroparenchymal fibroleastosis like lesions and apical cap
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Table. Demographic and clinical characteristics of patients.
All patients
(N = 105)

PPFE (-)
(N = 86)

PPFE (+)
(N = 19)

P

Female

93 (88.5)

77 (89.5)

16 (84.2)

0.45

Age, years

49.5 (12.4)

47.9 (12.2)

56.6 (11.3)

0.005a

Disease duration, years, median (Q1-Q3)

6.8 (2.0–13.6)

5.6 (1.4–11.2)

15.7 (6.6–18.9)

0.002b

Follow-up duration, years, median (Q1-Q3)

6.2 (2.5–8.5)

6.6 (3.3–8.8)

2.3 (1.5–7.4)

0.017b

Diffuse/limited disease

33/72

27/59

6/13

0.98

Antinuclear antibody (+)

100 (95.2)

82 (95.3)

17 (89.4)

1.000

Antitopoisomerase (+)

71 (67.6)

59 (68.6)

12 (63.1)

0.87

Anticentromere (+)

3 (2.8)

2 (2.3)

1 (5.2)

0.43

Digital ulcers (active or previous)

62 (60.2)

50 (59.5)

12 (63.2)

0.77

Myositis

9 (8.5)

6 (7.0)

3 (15.8)

0.20

Pulmonary arterial hypertension

9 (8.5)

6 (7.0)

3(15.8)

0.20

Usual interstitial pneumoniae

9 (8.5)

4 (4.7)

5 (26.3)

0.01

The extent of ILD on HRCT
Limited (<20%)
Extensive (>20 %)

57 (54.3)
48 (45.7)

52 (60.5)
34 (30.5)

5 (26.3)
14 (73.7)

0.01

Emphysema on HRCT

10 (9.5)

9 (10.5)

1 (5.3)

0.68

Esophageal dilatation on HRCT

97 (92.4)

79 (91.9)

18 (94.7)

1.000

Forced vital capacity %, median (Q1-Q3)*

81 (67–92)

82 (72–93)

64 (52–83)

0.005b

64 (60.9)
43 (40.9)
13 (12.3)
42 (40.0)

50 (58.1)
34 (39.5)
11(12.8)
33 (38.4)

14 (73.7)
9 (47.4)
2 (10.5)
9 (47.4)

0.20
0.53
1.000
0.47

Treatment
Cyclophosphamide
Mycophenolatemofetil
Rituximab
Vasodilators (ERA, PDE5-i, intravenous
prostanoids)

ILD; interstitial lung disease, HRCT; high resolution computed tomography, ERA; endothelin receptor antagonists, PDE5-i:
phosphodiesterase 5 inhibitors.
Values are n (%) and mean (SD) unless otherwise specified.
a
Student’s t-test was used.
b
Mann-Whitney U test was used.
* FVC measurements were available in 73 and 13 patients with and without PPFE, respectively.

slightly more frequent in patients with PPFE (15.8% vs.
7.0%, p = 0.20). Spontaneous pneumothorax occurred in
1 patient with definite PPFE during follow-up. Fourteen
patients with PPFE had consecutive HRCT scans. During
a median time period of 3.5 (2.4–6.3) years, 5 patients had
progression of PPFE. The median time period between the
index and follow-up HRCT scan was higher in patients
with progression of PPFE than stabile ones (6 (4–13.5) vs.
3 (2–4.2) years, p = 0.09).
4. Discussion
The aim of this study was to present data about the
prevalence and clinical associations of radiologic PPFE in
a single-center cohort of SSc-ILD patients. The prevalence
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of PPFE was found as 18.1%. Patients with PPFE more
frequently had radiological UIP patterns and lower FVC
values than PPFE (-) ones.
The prevalence of radiologic PPFE in our cohort is in
line with a recent study analyzing SSc-ILD cohorts of two
referral centers from Italy and UK. The frequency of PPFE
was found 18.4% in the UK cohort and %17.5 in the Italian
cohort [8]. Another study reported a higher frequency
of radiologic PPFE-like lesions in patients with SSc-ILD
(6/14, %43) however, their definition did not exclude
apical cap which is a relatively common finding in HRCT
[18].
Patients with PPFE had more severe restrictive lung
disease in our study. Longer disease duration and higher
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age of PPFE (+) patients are potential explanations for
this finding. On the other hand, in a previous study on
SSc-ILD, Bonifazi et al. found that patients with PPFE
had trend towards lower FVC values (74 vs. 80, p = 0.1)
and higher annual decline in FVC compared to PPFE
(-) patients despite comparable disease duration and
average ILD extent on HRCT [8]. Similarly, Enomoto
et al. reported lower FVC values in PPFE (+) patients at
the time of ILD diagnosis in a connective tissue disease
associated ILD (CTD-ILD) cohort (67% vs. 77%, p: 0.15)
[18]. Previous studies showed that both lower and upper
lobe involvement more frequently occurs in PPFE (+)
patients with CTD-ILD [18]. Reticular abnormalities and
ground glass opacities are also known to be more intense
in these patients compared to PPFE (-) ones [18]. Similar
to previous studies, radiologic UIP patterns were more
frequent in PPFE (+) patients in our cohort. In addition,
patients with extensive (>20%) lung fibrosis were more
frequent in PPFE (+) group and PPFE was not observed
in any patients with cellular NSIP. PPFE with a lower lobe
predominant UIP pattern is a previously known entity
[12,19,20] and shown to be more frequent in secondary
PPFE than primary PPFE [19]. Radiologic PPFE-like
appearance may be a result of apical involvement by UIP
in these patients. In a pathological examination, Enomoto
et al. showed upper lobe UIP in 2 of 3 patients with
radiologically PPFE-like lesions. Taken together, lower
FVC in PPFE (+) patients in our study may be explained
by more extensive involvement of lungs by UIP.
The negative impact of PPFE on the prognosis of
interstitial pneumoniaes such as idiopathic pulmonary
fibrosis (IPF) has been previously defined [19]. Bonifazi et
al. reported that the presence of radiologic PPFE was also
associated with poorer prognosis in SSc-ILD. Similarly,
Enomoto et al. showed that presence of PPFE is an

independent predictor of death due to respiratory causes
in patients with CTD-ILD. The mechanism of the impact
of PPFE on prognosis in CTD-ILD is unclear. Besides a
possible direct effect on prognosis, it may simply be an
indicator of extensive lung fibrosis. Although our data
did not allow us to perform survival analysis, more deaths
occurred in PPFE (+) patients despite a shorter follow-up
duration. However, longer disease duration and higher age
in PPFE (+) group likely might have biased our results.
Nevertheless, the presence of PPFE may be of value in
prognostic evaluation of patients with SSC-ILD, as it can
be easily assessed on HRCT in daily practice.
Retrospective single-center design and a limited
number of patients are major limitations of this study.
Second, we could not provide information about the
infections which are one of the most common etiologies of
PPFE. Lastly, longer disease duration at first HRCT did not
allow us to draw any conclusion about prognostic value of
PPFE in Ssc-ILD.
To conclude, PPFE on HRCT is not an uncommon
lesion in SSc-ILD and associated with radiologic UIP
pattern, more extensive lung involvement, and worse lung
functions. Further studies including patients with shorter
disease duration are needed to elucidate the prognostic
value of PPFE in SSc-ILD.
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